UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 20, 2020
Merit Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Utah |
| 0-18592 |
| 87-0447695 |
(State or other jurisdiction of | | (Commission | | (I.R.S. Employer |
incorporation or organization) | | File Number) | | Identification No.) |
| | |
1600 West Merit Parkway |
| |
South Jordan, Utah | | 84095 |
(Address of principal executive offices) | | (Zip Code) |
(801) 253-1600
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Common Stock, no par value | | MMSI | | NASDAQ Global Select Market System |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS.
On January 20, 2020, Kent W. Stanger notified the Environmental, Social and Governance Committee of the Board of Directors (the “Board”) of Merit Medical Systems, Inc. (the "Company") that he does not intend to stand for re-election as a director of the Company at the Company’s 2020 Annual Meeting of Shareholders (the “Annual Meeting”). Although the Board has not established the date for the Annual Meeting, the Board currently anticipates the Annual Meeting will be held in or about the end of May, 2020. Mr. Stanger has served as a director of the Company since September 1987. Mr. Stanger's decision not to stand for reelection is for personal reasons, and not due to any disagreement with the directors or management of the Company.
After considering Mr. Stanger’s decision, on January 21, 2020 the Board voted unanimously to reduce the size of the Board from ten to nine directors, effective as of the Annual Meeting.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
EXHIBIT NUMBER |
| DESCRIPTION |
| | |
104 | | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MERIT MEDICAL SYSTEMS, INC. | |
| | |
| | |
Date: January 21, 2020 | By: | /s/ Brian G. Lloyd |
| | Brian G. Lloyd |
| | Chief Legal Officer and Corporate Secretary |
3